The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Levothyroxine Sodium
Levothyroxine Sodium · LEVOTHYROXINE SODIUM 40 ug/mL · Injection, Solution · Intravenous · Fresenius Kabi USA, LLC
NDC 63323-0890-10 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 5 mL in 1 VIAL, SINGLE-DOSE · NDA · View full market →
One drug, every price
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
ⓘ How this was built
Data sources
- CMS NADAC (pharmacy acquisition, weekly)
- CMS Part B ASP quarterly payment limits
- CMS Maximum Fair Prices (IRA negotiated, NDC-level)
- Medicare Part D Spending by Drug (data.cms.gov, name-matched)
- VA FSS / Big4 federal contract prices (va.gov, twice monthly)
- ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
- California SB-17 WAC filings (list price, per package)
Method
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
- Medicare Part B pays (ASP+6%)$6.84per billing unit (10 MCG)HCPCS J0651 · Jul 1, 2026
- Part D plans paid (avg)$0.0923per dosage unitgross, before rebates — matched by drug name · 2024
- Federal ceiling (Big4)$117.43per package of 1X5MLFresenius Kabi, LLC · Jan 1, 2026
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$221.72
Reported to Texas DSHS · 2026 annual filing · Fresenius Kabi USA
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 10 MCG
$6.836
HCPCS J0651 · Jul 1, 2026 quarter · typically ASP + 6%
Medicaid spend (2025)
$9,916
11 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Fresenius Kabi USA, LLCUnited Statesanalysis · manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $17.32 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA210632
- TE code
- —
- Approval date
- Apr 11, 2019
- Patents / exclusivity
- 12 patents, 0 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| patent | 9782376 | Dec 1, 2036 |
| patent | 9782376 | Dec 1, 2036 |
| patent | 11135190 | Dec 1, 2036 |
| patent | 10398669 | Dec 1, 2036 |
| patent | 11135190 | Dec 1, 2036 |
| patent | 12636270 | Dec 1, 2036 |
| patent | 11135190 | Dec 1, 2036 |
| patent | 10398669 | Dec 1, 2036 |
| patent | 12636270 | Dec 1, 2036 |
| patent | 9782376 | Dec 1, 2036 |
| patent | 10398669 | Dec 1, 2036 |
| patent | 12636270 | Dec 1, 2036 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Levothyroxine Sodium (Injection, Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Fresenius Kabi USA, LLC | LEVOTHYROXINE SODIUM 20 ug/mL | Jul 15, 2026 | Sep 3, 2026 |
| Fresenius Kabi USA, LLC | LEVOTHYROXINE SODIUM 100 ug/mL | Jul 15, 2026 | Sep 2, 2026 |
| Fresenius Kabi USA, LLC | LEVOTHYROXINE SODIUM 40 ug/mL | Jul 15, 2026 | Sep 2, 2026 |
| Hikma Pharmaceuticals USA Inc. | LEVOTHYROXINE SODIUM 100 ug/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Levothyroxine Sodium — NDC 63323-0890-10," retrieved September 3, 2026, https://drugdashboards.com/drug/63323089010.
Free to cite with attribution — see how the data is put together.